GSK Moves mRNA Flu Shot Into Phase 3 on a New Formulation
GSK is taking its mRNA seasonal flu vaccine into late-stage testing with a reformulated candidate after Phase 2 data showed stronger immune responses than conventional shots.
GSK said on Tuesday, September 1, 2026, that it will begin a Phase 3 trial of its mRNA seasonal influenza vaccine using a newer formulation, after the candidate produced higher immune responses than traditional flu vaccines in a Phase 2 study; GSK shares traded at 50.76, up 1.01%, as of 15:20 GMT.
GSK (LSE/NYSE listing; see market data below) said on Tuesday that it will begin a Phase 3 trial of its messenger RNA vaccine against seasonal influenza, moving the programme into the final and most expensive stage of clinical testing. The decision follows a Phase 2 study in which the candidate produced what the company described as “higher immune responses” than traditional influenza vaccines.
The late-stage study will test a newer formulation of the candidate rather than the exact version carried through mid-stage work — a detail that matters more than it might sound, because it tells you the company has been iterating on the delivery and composition of the shot while the immunogenicity signal was being generated.
Shares in GSK were quoted at 50.76, up 1.01% on the day, as of 15:20 GMT on Tuesday, against a previous close of 50.25 and an intraday range of 50.51 to 51.26. The move came on a soft session for the broad market: the S&P 500 tracker (SPY) was down 0.48% at $763.33, the Nasdaq 100 tracker (QQQ) down 1.02% at $709.48, and the Dow tracker (DIA) down 0.34% at $529.76.
Why the reformulation is the real news
mRNA influenza programmes across the industry have run into a recurring problem: the technology reliably generates strong antibody responses, but the reactogenicity — sore arms, fever, fatigue — has tended to be higher than with the egg- or cell-based flu shots people already tolerate well. A flu vaccine is not a pandemic vaccine. It is a product given to hundreds of millions of healthy adults every autumn, many of them elderly, and the tolerability bar is set by what pharmacies already dispense for a few dollars a dose.
That is the context in which a “newer formulation” entering Phase 3 should be read. Companies change formulation between Phase 2 and Phase 3 for a limited set of reasons: to lower the dose needed for the same response, to improve stability and cold-chain handling, or to reduce side effects. GSK has not, on the facts disclosed, specified which of those it is chasing. But the sequencing — good immunogenicity in Phase 2, then a revised formulation into the pivotal study — is consistent with a company that believes it has solved the response question and is now optimising everything around it.
What GSK has to beat
The comparator here is not a placebo. Seasonal influenza vaccination is a mature, competitive market with established products, and any new entrant has to demonstrate it is better than what exists — not merely that it works. GSK's own Phase 2 framing, higher immune responses than traditional vaccines, sets that bar explicitly.
The strategic case for mRNA in flu rests on speed. Conventional influenza manufacturing requires strain selection months ahead of the season and a long production cycle, which means the strains in the vial can drift away from the strains actually circulating by the time the vaccine reaches an arm. An mRNA platform compresses that timeline. If a manufacturer can pick strains later and still deliver on schedule, the resulting vaccine should be better matched — and better matched translates into better real-world effectiveness even if the laboratory immune response were merely equivalent.
That is the prize GSK and its rivals in mRNA influenza are competing for. Several large vaccine developers have been pursuing the same target, and the field has produced mixed results, with some candidates showing strong responses against influenza A strains and weaker performance against B strains. Whether GSK's reformulated candidate closes that gap is precisely what a Phase 3 programme is designed to establish, and the company has not released strain-level detail.
Where this fits in GSK's vaccine franchise
Vaccines are a defining part of GSK's identity as a UK pharmaceutical company, and the division has been under pressure from a maturing shingles market and a US respiratory syncytial virus market that has been reshaped by shifting immunisation recommendations. A successful seasonal flu franchise would be a durable, annually recurring revenue line — the kind of predictable demand that vaccine businesses are valued on.
A successful seasonal flu franchise would be a durable, annually recurring revenue line — the kind of predictable demand that vaccine businesses are valued on.
It would also give GSK a validated mRNA manufacturing base. That has strategic value beyond influenza: the same platform underpins combination respiratory vaccines, where a single injection covers flu plus another pathogen. Combination shots are widely seen as the commercial endgame in respiratory vaccination, because they solve the pharmacy's biggest problem, which is getting the patient to show up at all.
What to watch from here
Three things will determine whether Tuesday's announcement, first reported by Endpoints News, matures into a commercial product.
- Tolerability in the pivotal data. Immunogenicity is table stakes now. The safety and reactogenicity profile of the new formulation, in older adults especially, is the read that will decide the programme.
- Strain breadth. Regulators expect coverage across the influenza A and B strains in the seasonal formulation. Uneven performance is the historic weak point of mRNA flu candidates.
- Trial timing versus flu seasons. Efficacy studies in seasonal influenza are hostage to when and how hard the virus circulates. A light season can stretch a programme by a full year.
For shareholders, none of this resolves quickly. Phase 3 vaccine trials in seasonal disease run across hemispheres and seasons, and the gap between the start of a pivotal study and a regulatory filing is measured in years, not quarters. Tuesday's modest move in the shares — a gain of roughly a percentage point on a day when all three major US equity benchmarks were lower — reads as an acknowledgement that the programme has cleared a decision gate, not as a repricing of the vaccine franchise.
The more informative signal is behavioural. Advancing a reformulated candidate into Phase 3 commits real capital to a manufacturing configuration. Companies do not make that commitment on a marginal data set. GSK has, in effect, told the market which version of its flu vaccine it intends to sell.
Key facts
- GSK share price: 50.76, +1.01%, as of 15:20 GMT, Sept. 1, 2026
- Trial stage: Phase 3 (late-stage) seasonal influenza mRNA vaccine
- Phase 2 result: Higher immune responses than traditional flu vaccines
- Key change: Pivotal study uses a newer formulation of the candidate
Frequently asked questions
What did GSK announce about its mRNA flu vaccine?
On Tuesday, September 1, 2026, GSK said it will begin a Phase 3 trial — the final and largest stage of clinical testing — of its messenger RNA vaccine for seasonal influenza. The decision follows a Phase 2 study in which the candidate generated higher immune responses than traditional influenza vaccines. The pivotal trial will use a newer formulation of the shot.
Why does the change in formulation matter?
Companies typically reformulate between mid- and late-stage testing to lower the required dose, improve stability, or reduce side effects such as fever and fatigue. Because seasonal flu shots are given to hundreds of millions of healthy people annually, tolerability is a decisive commercial factor. GSK has not specified which objective the newer formulation is intended to address.
How did GSK shares react?
GSK traded at 50.76 as of 15:20 GMT on September 1, 2026, up 1.01% from a previous close of 50.25, within an intraday range of 50.51 to 51.26. That gain came on a weaker session for US benchmarks, with the S&P 500 tracker down 0.48%, the Nasdaq 100 tracker down 1.02% and the Dow tracker down 0.34%.
What advantage would an mRNA flu vaccine have?
Speed. Conventional influenza vaccines require strain selection months before the season and a long manufacturing cycle, so the strains in the vial can drift from those circulating. An mRNA platform compresses that timeline, potentially allowing later strain selection and a better match, which improves real-world effectiveness even without a stronger laboratory immune response.
What has historically held mRNA flu vaccines back?
Two issues recur across the field. First, reactogenicity — the sore arms, fever and fatigue associated with mRNA shots — has tended to exceed that of established egg- or cell-based flu vaccines. Second, several candidates have shown strong responses against influenza A strains but weaker performance against influenza B, which regulators expect seasonal vaccines to cover.
How long before results are available?
Phase 3 seasonal influenza trials depend on how heavily the virus circulates in a given season and are often run across both hemispheres. The interval between starting a pivotal study and filing for regulatory approval is typically measured in years rather than quarters. GSK has not disclosed a timeline for readout or submission.
Sources
Photo: SHVETS production · Pexels Licence — source
